UC Irvine

UC Irvine Previously Published Works

Title

Novel RAS Inhibitors Poricoic Acid ZG and Poricoic Acid ZH Attenuate Renal Fibrosis via a Wnt/ β -Catenin Pathway and Targeted Phosphorylation of smad3 Signaling.

Permalink

<https://escholarship.org/uc/item/94c0j082>

Journal

Journal of agricultural and food chemistry, 66(8)

ISSN

0021-8561

Authors

Wang, Ming
Chen, Dan-Qian
Chen, Lin
[et al.](#)

Publication Date

2018-02-01

DOI

10.1021/acs.jafc.8b00099

Peer reviewed

Article

Novel RAS inhibitors poricoic acid ZG and poricoic acid ZH attenuate renal fibrosis via Wnt/ β -catenin pathway and targeted phosphorylation smad3 signaling

Ming Wang, Dan-Qian Chen, Lin Chen, Hui Zhao, Dan Liu, Zhi-Hao Zhang, Nosratola D. Vaziri, Yan Guo, Ying-Yong Zhao, and Gang Cao

J. Agric. Food Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.jafc.8b00099 • Publication Date (Web): 31 Jan 2018

Downloaded from <http://pubs.acs.org> on February 13, 2018

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.

ACS Publications

Novel RAS inhibitors poricoic acid ZG and poricoic acid ZH attenuate renal fibrosis via Wnt/ β -catenin pathway and targeted phosphorylation smad3 signaling

Ming Wang^{†, @}, Dan-Qian Chen^{†, @}, Lin Chen[†], Dan Liu[†], Hui Zhao[†], Zhi-Hao Zhang[†], Nosratola D. Vaziri[‡], Yan Guo^{†, §}, Ying-Yong Zhao^{*, †, ‡}, Gang Cao^{*, §}

[†] Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, School of Life Sciences, Northwest University, No. 229 Taibai North Road, Xi'an, Shaanxi 710069, China

[‡] Division of Nephrology and Hypertension, School of Medicine, University of California Irvine, Irvine, California 92897, USA

[§] Department of Internal Medicine, University of New Mexico, Comprehensive Cancer Center, Albuquerque, New Mexico, 87131, USA

[§] School of Pharmacy, Zhejiang Chinese Medical University, No. 548 Binwen Road, Hangzhou, Zhejiang 310053, China

[@] Both the authors contributed equally to the research.

Corresponding authors:

Professor Ying-Yong Zhao, PhD, MD

School of Life Sciences, Northwest University, No. 229 Taibai North Road, Xi'an, Shaanxi 710069, China, Tel: +86 29 88305273; Fax: +86 29 88303572, E-mail: zyy@nwu.edu.cn; zhaoyybr@163.com

Scientific Reports, American Journal of Nephrology, Editorial Board

Professor Gang Cao, PhD

School of Pharmacy, Zhejiang Chinese Medical University, No. 548 Binwen Road, Hangzhou, Zhejiang 310053, China; Tel/Fax: +86 571 87195895; E-mail: caogang33@163.com

ABSTRACT: Renal fibrosis is a common endpoint of the progression of chronic kidney disease (CKD). Suppressing the development and progression of renal fibrosis is essential in the treatment of kidney disease. Our previous study demonstrated that the ethyl acetate extract of the surface layer of *Poria cocos* exhibited beneficial anti-tubulointerstitial fibrosis. In this study, we isolated new diterpene (PZF) and triterpenes (PZG and PZH) and examined their anti-fibrotic effect. TGF- β 1 upregulated the collagen I protein expression in HK-2 cells and PZG and PZH treatment significantly inhibited the upregulated collagen I expression (TGF group 0.59 ± 0.08 vs TGF+PZG group 0.36 ± 0.08 , $P < 0.01$; TGF+PZH group 0.39 ± 0.12 , $P < 0.01$). Triterpenes, PZG and PZH, exhibited a stronger inhibitory effect on renal fibrosis and podocyte injury than PZF. PZG and PZH further showed a stronger inhibitory effect on the activation of renin-angiotensin system (RAS) caused by renal injury than PZF. Additionally, PZG and PZH markedly inhibited the activation of Wnt/ β -catenin signaling, which plays an important role in fibrogenesis. Interestingly, PZG and PZH suppressed TGF- β /Smad pathway by selectively inhibiting the phosphorylation of Smad3 through blocking the interactions of SARA with TGF β I and Smad3. The analysis of the structure-activity relationship demonstrated that the anti-fibrotic effect was closely associated with the first six-membered ring structure and the number of carboxyl groups in this type of compounds. These novel tetracyclic triterpenoid compounds provided the potential lead compounds for the research and development of anti-fibrosis drug and they possessed the potential to be utilized as RAS inhibitors.

KEYWORDS: Renin-angiotensin system; *Poria cocos*; poricoic acid; Wnt/ β -catenin pathway; TGF- β /Smad pathway

■ INTRODUCTION

Renal fibrosis is the final pathways of progression of chronic kidney disease (CKD) to end stage renal disease (ESRD). The characteristic of renal fibrosis is the increase of myofibroblasts, inflammatory cells infiltration, and excessive extracellular matrix (ECM) accumulation in renal interstitium¹⁻³. Renal fibrosis is closely related to TGF- β /Smad signaling pathway⁴. Transforming growth factor- β 1 (TGF- β 1) plays an irreplaceable role in the occurrence and the development of renal fibrosis. TGF- β 1 is a potent cytokine that controls the transcription of many ECM genes. The

epithelial-mesenchymal transition (EMT), a critical process of tubulointerstitial fibrosis (TIF), is also driven by TGF- β 1^{5, 6}. Smad is a significant downstream gene of TGF- β 1 in the fibrogenesis. TGF- β 1 leads to fibrogenic effect by the upregulation of Smad2 and Smad3 expression and the downregulation of Smad7 expression.

Renin-angiotensin system (RAS) and Wnt/ β -catenin pathways also play an important role in renal fibrosis^{7, 8}. All of the RAS components are present in the kidney tissues and activation of intrarenal RAS is a key component in the development and progression of renal fibrosis⁹. RAS consists of angiotensinogen (ATG), renin, angiotensin-converting enzyme (ACE), angiotensin II (Ang II), angiotensin II type 1 receptor (AT1) and angiotensin II type 2 receptor (AT2). Ang II is a key mediator in RAS-induced renal fibrosis. It stimulates TGF- β 1 expression in the kidney, or directly phosphorylates Smad2 and Smad3 to promote fibrosis¹⁰⁻¹². Although silent in adult kidney, Wnt/ β -catenin is reactive after kidney injury. Wnt/ β -catenin signaling induces renal fibrosis through promoting downstream target genes expression, most of which are fibrosis-related genes, including snail, twist, fibronectin, matrix metalloproteinase-7 (MMP-7), fibroblast specific protein-1 (Fsp-1), plasminogen activator inhibitor-1 (PAI-1) and RAS components¹³.

Targeting inhibition of RAS/Wnt/ β -catenin axis achieved better anti-fibrotic effect than targeting a single pathway, which indicated a new therapeutic strategy to mitigate renal fibrosis⁸.

Recent studies demonstrated that small molecular weight natural products exhibited a good therapeutic effect on renal fibrosis¹⁴⁻¹⁹. Our previous studies showed that the ethanol extract of the surface layer of *Poria cocos* (SLPC) enhanced diuresis and was highly effective in the treatments of CKD^{20, 21}. Further investigation indicated that the ethyl acetate extract of SLPC exhibited processes remarkable diuretic and anti-fibrotic effects²²⁻²⁵. In the present study, we investigated the renoprotective effect of three compounds with different skeletons isolated from the ethyl acetate extract of SLPC. The three newly found and reported compounds include one new diterpene poricoic acid ZF (PZF) and two new triterpenes poricoic acid ZG (PZG) and poricoic acid ZH (PZH). TGF- β 1 and Ang II were used to stimulate HK-2 cells and podocytes to induce renal injury. The treatment with PZF, PZG and PZH inhibited renal fibrogenesis, and the

anti-fibrotic effect of PZF, PZG and PZH were mediated by the suppression of RAS, TGF- β /Smad3 and Wnt/ β -catenin signaling pathways.

■ MATERIALS AND METHODS

Chemicals and Instruments. HPLC-grade methanol and acetonitrile was purchased from Baker Company (Baker Inc., USA). AR grade methanol, ethanol and acetonitrile were purchased from Tianjin Guangfu Fine Chemical Research Institute (Tianjin, China). Chemicals were purchased from Thermo Fisher Scientific (New York, USA), unless indicated otherwise. Ultra high purity water (UHP) was prepared by a Millipore-Q (France). DMEM-F12, DMEM and fetal bovine serum were purchased from Gibco (Carlsbad, USA). Lipofectamine RNAiMAX was purchased from Invitrogen (New York, USA). The recombinant human TGF- β 1 protein and recombinant human ANG II protein were purchased from R&D system (New York, USA). The losartan (LOS) was purchased from Selleck (Shanghai, China). Other chemicals were of analytical grade and their purity was above 99.5%.

Infrared (IR) spectrum was analyzed by using a Perkin Elmer FTIR system and Spectrum 2000 spectrophotometer (Perkin Elmer, USA). ^1D and ^2D NMR spectra were measured by using Bruker AM-500 spectrometer (Bruker, Zurich, Switzerland) with TMS as an internal standard. HRESI/MS were tested by an Agilent high-performance liquid chromatography (HPLC)-Thermo Finnigan LCQ Advantage ion trap mass spectrometer (California, USA). Column chromatography was carried out on silica gel (200-300 mesh, Qingdao Marine Chemical Inc., Shandong China). HPLC analysis and purification were performed on a Hanbon HPLC system equipped with a NP7000C serials pump and a NU3000 serials detector (Hanbon, Jiangsu, China) at 210 nm, and the column used was a YMC-Pack C₁₈ column (250 mm $\times$ 4.6 mm i.d., 5 μm).

Materials, extraction and isolation. SLPC were collected in Yunnan Province (China) and authenticated by Fang M. F. (Northwest University). The voucher specimen (16-09-12-01) was deposited in the herbarium of School of Life Sciences, Northwest University. The dried and powdered SLPC (20 kg) was extracted with 95% ethyl alcohol (100 L $\times$ 3) three times with at room temperature. The filtrates were combined and concentrated under reduced pressure until

elimination of ethyl alcohol to obtain crude extracts. Crude extracts (204 g) was fractionated by silica gel column chromatography (60 × 10 cm) with the use of a gradient solvent system of CHCl₃/MeOH (from 100:0 to 1:1) to give six fractions (FL1-FL6) according to TLC analysis. Fraction FL2 (12.0 g) was subjected to column chromatography using silica gel with CHCl₃-MeOH (97:7) as a solvent system, and PZF (9 mg) was obtained. Fraction FL5 (24.1 g) was fractionated by silica gel column chromatography with the use of a gradient solvent system of CHCl₃-MeOH (from 10:1 to 1:1) to obtain four fractions. The FL5-2 (2.7 g) was purified over reversed-phase HPLC with a gradient of MeOH-H₂O (79:21 to 83:17 v/v) to yield PZG (7 mg, t_R=17.2 min). Fraction FL5-3 (1.3 g) was further purified over reversed-phase HPLC (MeOH-H₂O, 75:25) to obtain PZH (6 mg, t_R=15.4 min).

Cell culture and treatment. Human kidney proximal epithelial cells (HK-2) and conditionally immortalized mouse podocytes (MPC5) were employed to test the anti-fibrotic effect of PZF, PZG and PZH on Ang II and TGF-β1 stimulation. HK-2 cells were cultured in DMEM-F12 supplemented with 10% fetal bovine serum, and MPC5 was cultured in DMEM containing 5.5 mM glucose with 10% fetal bovine serum. HK-2 cells were grown at 37°C with 5% CO₂, while MPC5 were grown at 33°C and differentiated at 37°C with 5% CO₂. The concentration of recombinant human TGF-β1 protein was 2.5 ng/ml, and the concentration of recombinant human ANG II protein was 1.0 μM. The 10 μM of PZF, PZG and PZH were used to treat Ang II and TGF-β1-stimulated cells. The 10 μM of LOS was used to treat HK-2 and MPC5. The cell viability of PZF, PZG and PZH were detected by CCK-8.

Analysis of cell viability by CCK-8. CCK-8 kit was purchased from EnoGene (Shanghai, China). The 1×10⁴ cells were cultured in 96-well plates and treated with different concentrations of ZF, PZG and PZH (0, 1, 10, 50, 100 μM) for 24 hours. Before added 10 μl CCK-8, 100 μl/well fresh medium was added into plates. After 3 hours incubation, the absorbance was detected at 450 nm on a microplate reader (Thermo, New York, USA). Six repeats were employed to determine the cell viability of each concentration.

Knockdown of Smad3 by siRNA. HK-2 cell lines were grown to 60% confluence and the siRNA targeting human Smad3 (5'-CCGCAUGAGCUUCGUCAAATT-3') and negative control (5'-UUCUCCGAACGUGUCACGUTT-3')

were transfected with 3 μ l of 10 μ M siRNA/well. Lipofectamine RNAiMAX was employed. The transfected cells were measured by Western blot and qRT-PCR.

Gene expression studies by qRT-PCR. Total RNA was isolated using a High Pure RNA Isolation Kit (Tokyo, Japan) according to the manufacturer's protocol. Total RNA was used for reverse transcription by a Transcriptor First Strand cDNA Synthesis Kit (Roche, Germany). Real time quantifications of target genes were assessed using SYBR® Premix Ex Taq™ II (Takara Bio, Japan). The housekeeping gene β -actin was used as the endogenous control. Samples were amplified with a precycling hold at 95°C for 30 seconds, 30 cycles of annealing and extension at 60 °C for 30 seconds by using BioRad CFX 96 Touch™ system (Bio-Rad, USA).

Western blot analysis. Protein expression was performed by Western blot analysis as described previously^{26, 27}. Cells were lysed in RIPA lysis buffer. Protein levels were measured by BCA Protein Assay Kit (23227, Thermo Scientific, USA) and normalized by immunoblotting with α -tubulin, GAPDH or histone H3 expression. Total protein was separated by SDS/PAGE and transferred to PVDF membranes (10600023, Amersham™ Hybond™, GE Healthcare, USA). Membranes were blocked in 1 $\times$ TBS with 0.1% Tween-20 (TBST) with 5% non-fat milk and then were incubated with the primary antibodies. Finally, membranes were washed, incubated with goat anti-rabbit (1:5000, ab6721, Abcam, USA), goat anti-mouse (1:5000, A21010, Abbkine, USA) or rabbit anti-goat (1:5000, A21110, Abbkine, USA) secondary antibodies, and developed with ECL (RPN2232, GE Healthcare, USA).

The following primary antibodies were employed (dilution): AGT (1:200, sc-7419, Santa Cruz Biotechnology, CA), renin (1:2000, 14291-1-AP, Proteintech, China), ACE (1:1000, sc-23908, Santa Cruz Biotechnology, CA), AT1 (1:800, ab124505, Abcam, USA), Wnt1 (1:1000, ab85060, Abcam, USA), dephosphorylated active non-phosphorylated β -catenin (1:2000, 05-665, Millipore, USA), β -catenin (1:1000, 610154, BD Transduction Laboratories, USA), collagen I (1:5000, ab34710, Abcam, USA), alpha smooth muscle actin (α -SMA, 1:300, ab7817, Abcam, USA), fibronectin (1:1000, ab2413, Abcam, USA), Snail1 (1:1000, ab180714, Abcam, USA), MMP-7 (1:400, ab5706, Abcam, USA), Twist (1:2000, ab50581, Abcam, USA), Fsp-1(S100A4, 1:1000, ab197896, Abcam, USA), transforming growth factor

β receptor I (TGF β RI, 1:1000, ab31013, Abcam, USA), transforming growth factor β receptor II (TGF β RII, 1:2000, ab186838, Abcam, USA), Smad2 (1:2000, 5339, CST, USA), p-Smad2 (1:2000, 3180, CST, USA), Smad3 (1:2000, 9523, CST, USA), p-Smad3 (1:2000, 9520, CST, USA), Smad4 (38454, CST, USA), Smad7 (1:500, sc-365846, Santa Cruz, USA) and α -tubulin (Proteintech Company, China).

Immunofluorescence staining. Indirect immunofluorescence staining was performed using an established procedure⁸. HK-2 cells were cultured on coverslip, and then fixed with fresh 4% paraformaldehyde solution. Normal goat serum was used to reduce non-specific background staining. Cells were stained with primary antibody followed by treatment with Alexa Fluor® 488 or 594-conjugated secondary antibody (Abcam, USA) for visualization. DAPI was employed to localize nuclear. Cells were visualized by using a laser-scanning confocal microscope (FV1000, Olympus, Japan) with FV10-ASW 4.0 VIEW.

Co-immunoprecipitation (CO-IP) analysis. After various treatments, HK-2 cells and podocytes were lysed by M-PER™ Mammalian Protein Extraction Reagent (78501, Thermo Scientific, USA). After preclearing with protein A/G (Immunoprecipitation Starter Pack, GE Healthcare, USA), cell lysates were incubated with anti-TGF β RI (1:100), anti-Smad2 (1:100) and anti-Smad3 (1:100) antibody overnight at 4°C, and then precipitated with protein A/G overnight at 4°C. The precipitated complexes were analyzed by western blotting.

Statistics analysis. All results were analyzed as means $\pm$ SD. GraphPad Prism software v 5.0 (San Diego, USA) was used to calculate the statistical differences among different groups by one-way ANOVA. *P* values smaller than 0.05 were considered as statistically significant.

■ RESULTS

Structure elucidation of isolated new compounds (PZF, PZG, PZH).

In this study, we isolated three novel compounds (PZF-PZH) from *P. cocos*. PZG and PZH were two novel triterpenes, and PZH was found to possess a unique 5(6),8(9)-diene at B/C rings, all of which was identified for the first time in triterpenes isolated from *P. cocos* (**Figure 1**). PZF was isolated as a yellow, amorphous powder. Its molecular formula,

C₃₀H₄₆O₃, was determined by HRESIMS molecular ion at m/z 453.1669 [M-H]⁻ and ¹³C NMR data. Its IR spectrum revealed the absorption bands of the aliphatic long-chain (2924 cm⁻¹), carbonyl (1711 cm⁻¹) and aromatic ring (1639, 1449 cm⁻¹) groups. The ¹H NMR spectrum of PZF indicated the presence of three protons in a trisubstituted aromatic ring at δ_H 7.29 (d, J = 8.2 Hz), 7.12 (dd, J = 8.1, 1.8 Hz) and 6.95 (d, J = 1.3 Hz); two quaternary methyl groups at δ_H 1.49 and 1.21; two singlet methyl groups both at δ_H 1.23. The ¹³C DEPT spectra of PZF revealed 30 carbon resonances, belonging to five methyls, 12 methylenes, six methines, and seven aromatic/olefinic quaternary carbons. According to the ¹³C NMR spectrum, there were the typical signals of one carbonyl carbon at δ_C 176.4 corresponding to C-18, one carboxyl carbon at δ_C 184.1 corresponding to C-20, and an isopropyl carbons at δ_C 34.3, 24.6 and 24.6 corresponding to C-15, C-16 and C-17, respectively. A chain structure from C-1' to C-9' connected with C-18 was confirmed by the important connectivities found in the heteronuclear multiple-bond connectivity (HMBC) spectrum (as shown in **Figure 1**) from H-19 (δ_H 1.49) to C-1' (δ_C 37.8), and from H-5 (δ_H 2.55) to C-18 (δ_C 176.4), and from H-1' (δ_H 1.84) to C-18 (δ_C 176.4). Furthermore, the HMBC signals from H-16, 17 (δ_H 1.23) to C-13 (δ_C 146.3) revealed that C-13 was connected with the isopropyl group. The relative stereochemistry of PZF was assessed by its nuclear overhauser effect spectroscopy (NOESY) spectrum (Fig. 1). The interactions between Me-19 (δ_H 1.49) and the protons at Me-21 (δ_H 1.21) revealed that they were on the same side of the molecule, while the nuclear Overhauser effect (NOE) between H-2 (δ_H 1.41) and H-5 (δ_H 2.55) suggested that Me-30 and H-18 were on the same side. All of these data established the structure of PZF as abieta-8,11,13-trien-18-pelargonyl-2-oic acid.

PZG was obtained as a white, amorphous powder. Its HRESIMS molecular ion at m/z 525.3176 [M+Na]⁺ and ¹³C NMR data were consistent with the molecular formula C₃₀H₄₆O₆ (calcd 525.3192). The IR spectrum indicated the presence of OH and C=C functional groups based on the absorptions at 3430 and 1644 cm⁻¹, respectively. The ¹H NMR data (Table 1) showed six methyls at δ_H 1.05 (s), 1.11 (s), 1.36 (s), 1.36 (s), 1.51 (s) and 1.75 (s), two olefinic protons at δ_H 5.30 (t) and 5.36 (br s), and an olefinic methylene at δ_H 4.85 (s) and 4.78 (s). The ¹³C NMR data (Table 2) revealed 30 carbon signals sorted by HSQC and DEPT. They included two carboxylic carbon at δ_C 177.0 and 179.2, six olefinic carbons at

δ_C 149.7, 142.3, 138.0, 120.8, 118.4 and 112.6, and one oxymethine carbon at δ_C 76.8. These data suggested that PZG belonged to the group of 3,4-seco-lanostan-7,9(11)-diene type triterpenes. The hydroxyl group was located at C-25, which was supported by the correlation from H-26, 27 (δ_H 1.36) to C-25 (δ_C 70.0), and from H-23 (δ_H 1.89) to C-25 (δ_C 70.0) in the HMBC experiment. The relative stereochemistry of PZG was assessed by its NOESY spectrum (Fig. 1). The NOESY cross peaks of H-16 (δ_H 4.53) and Me-18 (δ_H 1.11), as well as interactions between H-16 (δ_H 4.53) and H-20 (δ_H 2.98) suggested the α -orientation assignments of OH-16. Therefore, PZG was identified as (20R)-16 α ,25-dihydroxy-3,4-seco-lanosta-4(28),7,9(11)-triene-3,21-dioic acid.

PZH was isolated as a white amorphous powder. It gave a $[M+Na]^+$ ion in the HRESIMS at m/z 521.3226, which was consistent with a molecular formula of $C_{31}H_{46}O_5$ (calcd 521.3243). The IR spectrum indicated the presence of OH (3430 cm^{-1}) and C=C (1650 cm^{-1} and 1644 cm^{-1}) functional groups. The 1H NMR spectrum had seven methyls signals at δ_H 1.64 (3H, s, Me-30), 1.41 (3H, s, Me-28), 1.38 (3H, s, Me-19), 1.34 (3H, s, Me-29), 1.17 (3H, s, Me-18), 1.01 (3H, s, Me-27) and 1.00 (3H, s, Me-26), one olefinic proton at δ_H 6.56 (1H, s, H-6), and an olefinic methylene at δ_H 5.02 (s) and 4.87 (s). The ^{13}C DEPT and 1H NMR data and IR spectra of PZH indicated the presence of seven methyls, eight methylenes, six methines and ten quaternary carbons (including one carboxylic carbon at δ_C 179.5 corresponding to C-21). The presence of a tetrasubstituted double bond at C-8 and C-9 was supported by the correlation from H-30 (δ_H 1.64) to C-8 (δ_C 140.1), and from H-19 (δ_H 1.38) to C-9 (δ_C 162.9) in the HMBC experiment (**Figure 1**). Besides, the correlation between H-29 (δ_H 1.34), H-19 (δ_H 1.38), H-28 (δ_H 1.41) and C-5 (δ_C 186.6), as well as the correlation between H-6 (δ_H 6.56) and C-8 (δ_C 140.1) in the HMBC experiment suggested the location of a trisubstituted double bond at C-5 and C-6. The NOESY cross peaks of H-16 (δ_H 4.48) and Me-18 (δ_H 1.17), as well as interactions between H-16 (δ_H 4.48) and H-20 (δ_H 2.96) suggested the α -orientation assignments of OH-16. The ^{13}C NMR data of C-3 (δ_C 77.4) suggested the OH-3 was α -orientation, and it was supported by interactions between δ_H 4.60 (H-3) and δ_H 1.34 (H-29) in the NOESY experiment (Fig. 1). Hence, the structure of PZH was proposed as (20R)-3 α ,16 α -dihydroxy-7-oxo-24-methyl lanosta-5(6),8(9),24(31)-trien-21-oic acid.

The toxicity of PZF, PZG and PZH on HK-2 cells. To test the toxicity of PZF, PZG and PZH, the 0, 1, 10, 50 and 100 μM of PZF, PZG and PZH were incubated with HK-2 cells, respectively. CCK-8 method was used to test the value of cell viability after 24 hours incubation. The values of cell viability were 0.98 ± 0.06 , 0.99 ± 0.05 , 0.99 ± 0.03 , 1.03 ± 0.06 and 1.05 ± 0.03 after incubation with the concentrations of 0, 1, 10, 50 and 100 μM of PZF, respectively. The values of cell viability were 1.03 ± 0.04 , 0.99 ± 0.05 , 1.02 ± 0.03 , 0.98 ± 0.09 and 1.00 ± 0.07 after incubation with the concentrations of 0, 1, 10, 50 and 100 μM of PZG, respectively. The values of cell viability were 1.02 ± 0.03 , 0.99 ± 0.05 , 0.98 ± 0.04 , 1.01 ± 0.02 and 1.00 ± 0.06 after incubation with the concentrations of 0, 1, 10, 50 and 100 μM of PZH, respectively. In conclusion, PZF, PZG and PZH showed no toxicity on HK-2 cells. The 10 μM of PZF, PZG and PZH was used for subsequent experiments.

PZF, PZG and PZH attenuated TIF and podocyte injury induced by TGF- β 1 and Ang II. Collagen I, as one of most important component of fibrosis, is an important indicator in renal fibrosis, so we chose collagen I as an indicator for the determination of the inhibitory effect of the different concentrations of PZF, PZG and PZH in the TGF- β 1-induced HK-2 cells. The compound concentrations of 1, 10, 50 and 100 μM were tested for collagen I protein expression in HK-2 cells by induced TGF- β 1. As shown in **Figure 2A**, the concentration of 10 μM PZF, PZG and PZH exhibited a strong anti-fibrotic effect. Hence, we selected the 10 μM of PZF, PZG and PZH for the subsequent experiments.

We investigated the inhibitory effect of PZF, PZG and PZH on ECM accumulation, which was mainly expressed by myofibroblasts. TGF- β 1 directly accumulates transcription of many ECM genes in HK-2 cells. Ang II directly stimulates the expression of TGF- β 1, and directly stimulates Smads to induce renal fibrogenesis. In this study, both TGF- β 1 and Ang II significantly upregulated the expression of ECM, including collagen I, fibronectin and α -SMA (**Figure 2B-E**). E-cadherin is an epithelial cell marker and controls cell-cell junctions²⁸. E-cadherin can be viewed as an inhibitor of EMT²⁹. The protein expression of E-cadherin was significantly downregulated in HK-2 cells by inducing TGF- β 1 or Ang II (**Figure 2B-E**). The dysregulation caused by TGF- β 1 and Ang II were reversed by

triterpene PZG and PZH, but diterpene PZF hardly changed the dysregulation (**Figure 2B-E**). The upregulated mRNA expressions of collagen I, fibronectin, α -SMA and vimentin were suppressed by PZG and PZH, while downregulating E-cadherin mRNA expression induced by TGF- β 1 was reversed (**Figure 2F**). Interestingly, PZG exhibited a stronger inhibitory effect than PZH. Additionally, immunofluorescent staining also showed that upregulated vimentin expression were inhibited by PZG and PZH, whereas the expression of vimentin showed no fluctuation after given PZF, PZG or PZH alone (**Figure 2K**).

Next, we explored the protective effect of PZF, PZG and PZH on podocyte injury. TGF- β 1 and Ang II stimulation resulted in podocyte injury. The expression of podocyte-specific proteins, including podocin, nephrin, podocalyxin and synaptopodin, were significantly decreased after TGF- β 1 or Ang II stimulation (**Figure 2G-J**). Triterpene compounds PZG and PZH, rather than diterpene compound PZF, exhibited a protective effect on podocyte injury (**Figure 2G-J**). In conclusion, triterpene PZG and PZH showed a good therapeutic effect on TIF and podocyte injury. The different effects among triterpene compounds PZG, PZH and diterpene compound PZF were caused by the differences in the chemical structures. Our results indicated that triterpene was the active compound of SLPC in the treatment of renal fibrosis and podocyte injury. Interestingly, compared with the PZH, PZG showed stronger inhibitory effect on the TGF- β 1- and Ang II-induced TIF and podocyte injury. The loss of first intact six-membered-ring led to hydroxyl group in PZH transforming into carboxyl group in PZG. The increasing number of carboxyl group may be associated with the bioactivity of triterpene compound.

PZF, PZG and PZH inhibited the activation of RAS. Since the inhibition of activated RAS was beneficial to treatment of renal fibrosis and CKD ^{30, 31}, we examined the suppression of PZF, PZG and PZH on the activation of RAS induced by TGF- β 1 and Ang II. TGF- β 1 stimulation upregulated the protein expression of RAS components in HK-2 cells. After PZG and PZH treatment, activated RAS was inhibited, while PZF showed no effect on activated RAS (**Figure 3A,B**). Similarly, PZG and PZH significantly suppressed the activation of RAS caused by Ang II, while the inhibitory effect of PZF was weak (**Figure 3C,D**). Next, we examined the inhibitory effect of PZF, PZG and PZH on

activated RAS in podocyte. TGF- β 1 stimulation activated RAS, and the expressions of RAS components were increased. The significant decrease of RAS components were observed after PZG and PZH treatment, especially for ACE and AT1 (**Figure 3E,F**). PZG and PZH were also obviously decreased abnormal activated RAS caused by Ang II, whereas PZF showed a weak regulatory effect on this abnormality (**Figure 3G,H**).

PZF, PZG and PZH suppressed activated Wnt/ β -catenin and its downstream target genes expression.

Wnt/ β -catenin signaling is closely related to renal disease, especially for renal fibrosis³². Both TGF- β 1 and Ang II stimulated the activation of β -catenin and the transcription of downstream target genes, resulting in upregulation of downstream target genes. PZG and PZH significantly inhibited the upregulation of Wnt1, β -catenin, active non-phosphorylated β -catenin, snail1, twist, MMP-7, PAI-1 and Fsp-1 expression induced by TGF- β 1 and Ang II. However, PZF had no effect on Wnt/ β -catenin expression (**Figure 4A-D**). PZG and PZH also significantly inhibited the upregulated mRNA expression of Wnt1, Wnt2, Wnt3, Wnt3a, Wnt7a and Wnt8a (**Figure 4E**). Immunofluorescent staining also showed that PZG and PZH treatment have a significantly inhibitory effect on the β -catenin expression in HK-2 cells induced by TGF- β 1 (**Figure 4F**). PZG and PZH performed better than PZF on the suppression of activated Wnt/ β -catenin in renal epithelial cell. In podocyte, PZG and PZH attenuated the upregulating protein expression of Wnt1, β -catenin and active β -catenin induced by TGF- β 1 and Ang II, and the increase of target genes, such as snail1, twist, MMP-7, PAI-1 and Fsp-1, were reversed by PZG and PZH in podocytes (**Figure 4G-J**). PZG and PZH suppressed the activation of Wnt/ β -catenin in HK-2 cells and podocytes.

PZF, PZG and PZH selectively inhibits TGF- β /Smad3 pathway. Since TGF- β /Smad signaling played an irreplaceable role in the development and progression of renal fibrosis, we examined several important proteins in this pathway. We found that TGF- β 1 and Ang II significantly induced the expressions of TGF β RII, p-Smad2, p-Smad3 and Smad4, and significantly reduced Smad7 expression, which indicated activation of TGF- β /Smad signaling induced by TGF- β 1 and Ang II. TGF- β 1 or Ang II promoted the phosphorylation of Smad2 and Smad3 and upregulated the expression of p-Smad2 and p-Smad3, but did not change the expression of total Smad2 and Smad3. After PZH and PZG

treatment, the upregulation of p-smad3 was significantly inhibited. PZH and PZG only mitigated the upregulation of p-Smad3, but showed no effect on the dysregulation of p-Smad2, Smad2, Smad3, Smad4 and Smad7 in HK-2 cells, indicating Smad3 might be the intervention target of PZH and PZG (**Figure 5A-D**). Immunofluorescence staining results demonstrated that PZH and PZG showed a stronger inhibitory effect on p-Smad3, but PZF have no effect on p-Smad3 (**Figure 5E**). Similar results were observed in podocyte. TGF- β 1 and Ang II significantly upregulated p-Smad2 and p-Smad3, but PZH and PZG treatment only inhibited the upregulation of p-Smad3 (**Figure 5F-I**). PZH and PZG specifically attenuated increased p-Smad3 in HK-2 cells and podocytes, indicating PZH and PZG suppressed the phosphorylation of Smad3 induced by TGF- β 1 and Ang II.

PZF, PZG and PZH selectively interrupt the interactions of Smad3 with TGF β RI and SARA. To further explore the changes within TGF- β /Smad pathway, CO-IP were employed. First, we explored the interactions of TGF β RI and Smad2/3, founding that PZG and PZH only disturbed the interaction between TGF β RI and p-Smad3 (**Figure 6A,B**). The interactions of Smad2 with TGF β RI and TGF β RII was unaltered after PZF, PZG and PZH treatment (**Figure 6C,D**). Of note, PZG and PZH significantly weakened the interactions of Smad3 with TGF β RI and TGF β RII (**Figure 6E,F**). These results suggested that PZG and PZH specifically affected the interactions of Smad3 with TGF β RI and TGF β RII, instead of Smad2.

Since after TGF- β 1 stimulation, TGF β RI and Smad2/3 were connected by adaptor proteins such as Smad anchor for receptor activation (SARA)^{33, 34}, we explored the interactions of SARA with TGF β RI and Smad2/3. The interaction of Smad3 with SARA was obviously weakened by PZG and PZH treatment, but PZG and PZH performed no effect on the interaction of Smad2 with SARA (**Figure 6G-J**). As shown in **Figure 6K**, PZG and PZH specifically affected the interaction between SARA and Smad3 to suppress the phosphorylation of Smad3 and downregulated the expression of p-Smad3. These results indicated that Smad3 was the intervention target of PZF and PZH for suppressing TGF- β /Smad pathway and retard renal fibrosis.

PZF, PZG and PZH performed no anti-fibrotic effect after knockdown of Smad3. According to our results, Smad3 was the main target of PZG and PZH to retard renal fibrosis. Specific Smad3 siRNA was employed to further confirm the mechanism of PZG and PZH. We hypothesized that Smad3 was the primary target of PZG and PZH, which could explain the results that once Smad3 decreased, PZG and PZH lost the intervention target and thus showed no effect on renal fibrosis. First, we examined the inhibitory effect of specific Smad3 siRNA, founding that the protein expression of Smad3 was significantly downregulated in HK-2 cells induced by specific Smad3 siRNA (**Figure 7A**). Moreover, PZF, PZG and PZH had no influence on the process of RNAi, and would not upregulate Smad3 protein expression (**Figure 7B**). Interestingly, after knockdown Smad3, the anti-fibrosis of PZG and PZH significantly weakened, which provided the evidence that Smad3 was the main intervention target of PZG and PZH to mitigate renal fibrosis (**Figure 7C,D**).

Structure-activity correlation of PZF, PZG and PZH. Our study demonstrated that PZG exhibited a stronger inhibitory effect on the TGF- β 1- and Ang II-induced excessive ECM accumulation in HK-2 cells than PZH. According to the classification of compound chemical structure, PZG and PZH belonged to secolanostane tetracyclic triterpenoid compound and lanostane tetracyclic triterpenoid compound, respectively. The most important difference of two tetracyclic triterpenoid compounds is that the first six-membered ring in the secolanostane compounds is opening-ring chemical structure, but the first six-membered ring in lanostane compounds was intact six-membered ring chemical structure. The loss of first intact six-membered-ring led to hydroxyl group in PZH transformed into carboxyl group in PZG. Increasing number of carboxyl group may be associated with the bioactivity of triterpene compound. This result indicated that compound skeleton has an important effect on this type of secolanostane and lanostane tetracyclic triterpenoid compounds.

We compared the chemical structures of PZF and PZG. PZF and PZG both had chemical structures of three-membered ring and one carboxyl group in the parent nucleus. PZF had no inhibitory effect on TGF- β 1- and Ang II-induced cell injury, but PZG showed an inhibitory effect on TGF- β 1- and Ang II-induced cell injury. This result indicated that carboxyl group in PZG plays a crucial role in this type of compound.

■ DISCUSSION

Natural products have been widely used for the treatment of CKD and inhibition of renal fibrosis³⁵⁻³⁸. Our previous study demonstrated that SLPC exhibited a good therapeutic effect on CKD. The ethanol extract of SLPC ameliorates adenine-induced CKD by correcting the disturbance of amino metabolism and fatty acid metabolism²²⁻²⁴. On the basis of biological activity screening, the ethyl acetate extract is the main active fraction. Diterpene compound PZF and triterpene compounds PZG and PZH were isolated from SLPC. In the present study, we found that PZG and PZH significantly attenuated renal fibrosis caused by inducing TGF- β 1 and Ang II. PZG and PZH exert their effect by targeting the phosphorylation of Smad3, through inhibiting the interactions of Smad3 with TGF β RI with SARA. PZG and PZH exhibited a strong inhibitory effect on the activation of RAS and Wnt/ β -catenin signalings (**Figure 8**). However, PZF showed a weak effect, indicating triterpene components were the active component of SLPC, instead of diterpene components. These important bioactivities may be associated with the first six-membered ring and the number of carboxyl groups in secolanostane and lanostane tetracyclic triterpenoid compounds. This study provided activity targets for anti-fibrosis drug research and development.

Regardless of the type of initial injury to the kidney, renal fibrosis is the common final pathway of CKD to ESRD³⁹. The accumulation of ECM in the region between peritubular capillaries and tubules suppresses tubular function. ECM resulted in tubules injury, tubular necrosis and interstitial fibrosis. Fibrosis in glomerular led to reduced filtration and the loss of blood flow⁴⁰. With the increasing renal fibrosis area, the structural support of kidney was lost and kidney volume was decreased, which led to the loss of renal function. Suppression the development and progress of renal fibrosis is an indispensable component in CKD treatment. PZG and PZH showed excellent inhibitory effects on the increase expression of collagen I, fibronectin, α -SMA and the decrease expression of E-cadherin, but PZF had no influence on the dysregulation. Collagen I is an important component of fibrosis, and the decrease of collagen I is a vital parameter to measure the anti-fibrotic effect. Fibronectin is the component of ECM, and PZG and PZH inhibited fibronectin expression caused by inducing TGF- β 1 and Ang II in HK-2 cells and podocytes. α -SMA, the marker of

myofibroblasts, is mainly expressed in interstitium. After PZG and PZH treatment, α -SMA was downregulated, which indicated the inhibition of EMT. PZG and PZH exhibited a good anti-fibrotic effect, and this may involved in several signaling pathways, including RAS, TGF- β /Smad and Wnt/ β -catenin signaling.

RAS controls the blood pressure and fluid balance, and the activation of RAS is the major cause of hypertensive nephropathy ⁴¹. CKD caused hypertension and hypertension further activated RAS ⁴². RAS inhibitors, especially for angiotensin-converting enzyme inhibitor (ACEI) and angiotensin II type 1 receptor blocker (ARB), were the first-line therapy for CKD. ACEI and ARB antagonize Ang II to treat CKD. Ang II is a key mediator in RAS-induced renal fibrosis ⁴³. It stimulates TGF- β 1 and Smads to promote renal fibrogenesis ⁵. TGF- β 1 and Ang II induce the activation of RAS, while PZG and PZH suppress the activation of RAS by downregulating the expression of AGT, renin, ACE and AT1. Our study provides strong evidence that PZG and PZH are novel RAS inhibitors.

Wnt/ β -catenin signaling pathway is an evolutionarily conserved signaling pathway that is regulated by the amount of β -catenin ⁴⁴. Wnt/ β -catenin is silent in adult kidney tissue. However, Wnt/ β -catenin is reactivated in injured kidney, especially in CKD ^{7, 45}. Wnt/ β -catenin plays an opposite role in CKD compared to the RAS. Wnt/ β -catenin is advantageous in acute kidney injury for the restoration of kidney morphology and function ⁴⁶, but harmful in CKD ⁴⁷. The continuous activation of Wnt/ β -catenin drives acute kidney injury to CKD ⁴⁶. The upregulation of Wnt1 ligand, active β -catenin and β -catenin were observed after TGF- β 1 and Ang II stimulation, which indicated the activation of Wnt/ β -catenin pathway. PZG and PZH efficiently suppressed activated Wnt/ β -catenin and its downstream target gene expression. Upregulation of downstream target genes promoted renal fibrosis ⁸. Snail is a key transcription factor of EMT and facilitates fibroblast migration, and was downregulated by PZG and PZH. MMP-7 is the component of ECM and mediates the degradation of E-cadherin. MMP-7 was significantly inhibited by PZG and PZH. PAI-1 recruits myofibroblasts, and PAI-1 was significantly inhibited by PZG and PZH. The expression of fibrotic marker, Fsp-1, was also attenuated by PZG and PZH. PZG and PZH were better in the suppression of Wnt/ β -catenin and its downstream target gene expression than PZH.

367 Undoubtedly, TGF- β /Smad plays a central and dominant role in the initiation and development of renal fibrosis ⁴⁸⁻⁵⁰.
368 The TGF- β isoforms spread all over every cell type in mammals. The ubiquitous intracellular signaling cascade Smad
369 family protein is the major pathway of TGF- β signaling in renal fibrogenesis. The active TGF- β 1 binds to TGF β RII,
370 then recruits and phosphorylates TGF β RI, which results in the phosphorylation of Smads ⁵¹. The binding between
371 TGF β RI and Smads is mediated by adaptor proteins, including SARA. Among several Smads, Smad3 is recognized as
372 the most important one during fibrogenesis ^{10, 14}, which directly connected with promoter region of collagens to trigger
373 their production ⁵². Smad7 is negative regulator of TGF- β /Smad signaling, and the expression of Smad7 is significantly
374 downregulated in CKD. The expression of Smad7 is a Smad3-dependent mechanism, and suppresses TGF- β 1 in turn ⁵³.
375 Activated Smad protein complexes transfers into the nucleus and engage the transcription of target genes ⁵⁴. In the
376 present study, we tested the expression of primary proteins, and found that PZH and PZG inhibited the upregulation of
377 p-Smad3 expression specifically, which indicated the phosphorylation of Smad3 were suppressed. CO-IP showed that
378 After PZG and PZH treatment, the binding between TGF β RI and Smad3 was weak. Since TGF β RI phosphorylated
379 Smad3 by the connection of SARA, the suppressed phosphorylation of Smad3 may result in broken connection. The
380 interaction of SARA with TGF β RI and Smad3 were simultaneously suppressed. Interestingly, PZG and PZH had no
381 effect on the phosphorylation of Smad2 and the interactions of SARA with TGF β RI and Smad2. In conclusion, PZG
382 and PZH targeted the phosphorylation of Smad3 by inhibiting the connection of SARA with TGF β RI and Smad3 in the
383 TGF- β /Smad pathway. When the expression of Smad3 subsided, PZG and PZH lost the intracellular target. This
384 provided potent evidence for elucidating anti-fibrotic mechanism of PZG and PZH.

385 In this study, we isolated the active components of renoprotective effect of SLPC and elucidated their anti-fibrotic
386 mechanism. Triterpenes, PZG and PZH, are the major active components of SLPC to treat retard renal fibrosis, instead
387 of diterpene PZF. PZG and PZH exhibited a stronger anti-fibrotic effect than PZF though inhibiting RAS,
388 Wnt/ β -catenin and TGF- β /Smad signaling pathways. PZG and PZH demonstrated strong potential to be developed as
389 new RAS inhibitors. PZG and PZH specifically inhibited the phosphorylation of Smad3 and mitigated renal fibrosis.

The anti-fibrotic effect is closely associated with the first six-membered ring structure and the number of carboxyl groups in tetracyclic triterpenoid compounds. This study provides novel intervention targets for the development of effective anti-fibrotic agent.

Corresponding Author

*(Y.-Y.Z.) Tel: +86-29-88305273. Fax: +86-29-88303572. E-mail: zyy@nwu.edu.cn, zhaoyybr@163.com. (G.C.)
Phone: +Tel/Fax: +86 571 87195895; E-mail: caogang33@163.com

Funding

This study was supported by the National Natural Science Foundation of China (Nos. 81673578, 81603271).

Notes

The authors declare that there is no conflict of interest.

■ ABBREVIATIONS USED

ACE, angiotensin-converting enzyme; ACEI, angiotensin-converting enzyme inhibitor; AGT, angiotensinogen; AngII, angiotensin II; ARB, angiotensin II type 1 receptor blocker; AT1, angiotensin II type 1 receptors; CKD, chronic kidney disease; DEPT, distortionless enhancement by polarization transfer; ECM, extracellular matrix; EMT, epithelial-to-mesenchymal transition; Fsp-1, fibroblast-specific protein 1; HSQC, heteronuclear single-quantum coherence; LEF, lymphoid enhancer-binding factor; MMP-7, matrix metalloproteinase-7; NOESY, nuclear overhauser effect spectroscopy; PAI-1, plasminogen activator inhibitor-1; PZC, poricoic acid ZC; PZD, poricoic acid ZD; PZE, poricoic acid ZE; qRT-PCR, quantitative real-time PCR; RAS, renin-angiotensin system; siRNA, small interfering RNA; SLPC, the surface layer of *Poria cocos*; TCF, T-cell factor; TGF- β , transforming growth factor- β ; TGF β RI, transforming growth factor β receptor I; TGF β RII, transforming growth factor β receptor II; α -SMA, alpha smooth muscle actin.

■ REFERENCES

- 412 1. LeBleu, V. S.; Taduri, G.; O'Connell, J.; Teng, Y.; Cooke, V. G.; Woda, C.; Sugimoto, H.; Kalluri, R., Origin and
413 function of myofibroblasts in kidney fibrosis. *Nat Med* **2013**, *19*, 1047-1053.
- 414 2. Han, S. J.; Noh, M. R.; Jung, J. M.; Ishii, I.; Yoo, J.; Kim, J. I.; Park, K. M., Hydrogen sulfide-producing
415 cystathionine gamma-lyase is critical in the progression of kidney fibrosis. *Free radical biology & medicine* **2017**, *112*,
416 423-432.
- 417 3. Zhao, Y. Y.; Wang, H. L.; Cheng, X. L.; Wei, F.; Bai, X.; Lin, R. C.; Vaziri, N. D., Metabolomics analysis reveals
418 the association between lipid abnormalities and oxidative stress, inflammation, fibrosis, and Nrf2 dysfunction in
419 aristolochic acid-induced nephropathy. *Sci Rep* **2015**, *5*, 12936.
- 420 4. Jin, Y.; Ratnam, K.; Chuang, P. Y.; Fan, Y.; Zhong, Y.; Dai, Y.; Mazloom, A. R.; Chen, E. Y.; D'Agati, V.; Xiong,
421 H.; Ross, M. J.; Chen, N.; Ma'ayan, A.; He, J. C., A systems approach identifies HIPK2 as a key regulator of kidney
422 fibrosis. *Nat Med* **2012**, *18*, 580-8.
- 423 5. Wolf, G., Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth
424 factor-beta pathway. *Kidney Int* **2006**, *70*, 1914-1919.
- 425 6. Bottinger, E. P.; Bitzer, M., TGF-beta signaling in renal disease. *Journal of the American Society of Nephrology*
426 **2002**, *13*, 2600-2610.
- 427 7. Chen, D. Q.; Cao, G.; Chen, H.; Liu, D.; Su, W.; Yu, X. Y.; Vaziri, N. D.; Liu, X. H.; Bai, X.; Zhang, L.; Zhao, Y.
428 Y., Gene and protein expressions and metabolomics exhibit activated redox signaling and wnt/beta-catenin pathway are
429 associated with metabolite dysfunction in patients with chronic kidney disease. *Redox biology* **2017**, *12*, 505-521.
- 430 8. Chen, L.; Chen, D. Q.; Wang, M.; Liu, D.; Chen, H.; Dou, F.; Vaziri, N. D.; Zhao, Y. Y., Role of
431 RAS/Wnt/beta-catenin axis activation in the pathogenesis of podocyte injury and tubulo-interstitial nephropathy. *Chem*
432 *Biol Interact* **2017**, *273*, 56-72.

- 433 9. Xu, Z.; Li, W.; Han, J.; Zou, C.; Huang, W.; Yu, W.; Shan, X.; Lum, H.; Li, X.; Liang, G., Angiotensin II induces
434 kidney inflammatory injury and fibrosis through binding to myeloid differentiation protein-2 (MD2). *Scientific Reports*
435 **2017**, *7*, 44911.
- 436 10. Yang, F.; Huang, X. R.; Chung, A. C.; Hou, C. C.; Lai, K. N.; Lan, H. Y., Essential role for Smad3 in angiotensin
437 II-induced tubular epithelial-mesenchymal transition. *The Journal of pathology* **2010**, *221*, 390-401.
- 438 11. Rodriguez-Vita, J.; Sanchez-Lopez, E.; Esteban, V.; Ruperez, M.; Egido, J.; Ruiz-Ortega, M., Angiotensin II
439 activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent
440 mechanism. *Circulation* **2005**, *111*, 2509-17.
- 441 12. Remuzzi, G.; Perico, N.; Macia, M.; Ruggenenti, P., The role of renin-angiotensin-aldosterone system in the
442 progression of chronic kidney disease. *Kidney international. Supplement* **2005**, S57-65.
- 443 13. Zhou, L.; Li, Y.; Hao, S.; Zhou, D.; Tan, R. J.; Nie, J.; Hou, F. F.; Kahn, M.; Liu, Y., Multiple genes of the
444 renin-angiotensin system are novel targets of Wnt/beta-catenin signaling. *J Am Soc Nephrol* **2015**, *26*, 107-120.
- 445 14. Ai, J.; Nie, J.; He, J.; Guo, Q.; Li, M.; Lei, Y.; Liu, Y.; Zhou, Z.; Zhu, F.; Liang, M.; Cheng, Y.; Hou, F. F., GQ5
446 hinders renal fibrosis in obstructive nephropathy by selectively inhibiting TGF-beta-induced Smad3 phosphorylation. *J*
447 *Am Soc Nephrol* **2015**, *26*, 1827-1838.
- 448 15. Zhao, Y. Y.; Chen, H.; Tian, T.; Chen, D. Q.; Bai, X.; Wei, F., A pharmaco-metabonomic study on chronic kidney
449 disease and therapeutic effect of ergone by UPLC-QTOF/HDMS. *PLoS One* **2014**, *23*, e115467.
- 450 16. Ko, J.-W.; Shin, N.-R.; Park, S.-H.; Lee, I.-C.; Ryu, J.-M.; Kim, H.-J.; Cho, Y.-K.; Kim, J.-C.; Shin, I.-S., Silibinin
451 inhibits the fibrotic responses induced by cigarette smoke via suppression of TGF-beta 1/Smad 2/3 signaling. *Food and*
452 *Chemical Toxicology* **2017**, *106*, 424-429.
- 453 17. Zhao, Y. Y.; Zhang, L.; Mao, J. R.; Cheng, X. H.; R.C., L.; Zhang, Y.; Sun, W. J.,
454 Ergosta-4,6,8(14),22-tetraen-3-one isolated from Polyporus umbellatus prevents early renal injury in aristolochic
455 acid-induced nephropathy rats. *J Pharm Pharmacol* **2011**, *63*, 1581-1586.

- 456 18. Zhao, Y. Y.; Cheng, X. L.; Cui, J. H.; Yan, X. R.; Wei, F.; Bai, X.; Lin, R. C., Effect of
457 ergosta-4,6,8(14),22-tetraen-3-one (ergone) on adenine-induced chronic renal failure rat: a serum metabonomic study
458 based on ultra performance liquid chromatography/high-sensitivity mass spectrometry coupled with MassLynx i-FIT
459 algorithm. *Clin. Chim. Acta* **2012**, *413*, 1438-1445.
- 460 19. Zhao, Y. Y.; Shen, X.; Cheng, X. L.; Wei, F.; Bai, X.; Lin, R. C., Urinary metabonomics study on the protective
461 effects of ergosta-4,6,8(14),22-tetraen-3-one on chronic renal failure in rats using UPLC Q-TOF/MS and a novel MSE
462 data collection technique. *Process Biochem* **2012**, *47*, 1980-1987.
- 463 20. Zhao, Y. Y.; Cheng, X. L.; Wei, F.; Bai, X.; Lin, R. C., Application of faecal metabonomics on an experimental
464 model of tubulointerstitial fibrosis by ultra performance liquid chromatography/high-sensitivity mass spectrometry with
465 MS(E) data collection technique. *Biomarkers* **2012**, *17*, 721-729.
- 466 21. Feng, Y. L.; Lei, P.; Tian, T.; Yin, L.; Chen, D. Q.; Chen, H.; Mei, Q.; Zhao, Y. Y.; Lin, R. C., Diuretic activity of
467 some fractions of the epidermis of *Poria cocos*. *J Ethnopharmacol* **2013**, *150*, 1114-1118.
- 468 22. Zhao, Y. Y.; Lei, P.; Chen, D. Q.; Feng, Y. L.; Bai, X., Renal metabolic profiling of early renal injury and
469 renoprotective effects of *Poria cocos* epidermis using UPLC Q-TOF/HSMS/MSE. *J Pharm Biomed Anal* **2013**, *81- 82*,
470 202-209.
- 471 23. Zhao, Y. Y.; Li, H. T.; Feng, Y. L.; Bai, X.; Lin, R. C., Urinary metabonomic study of the surface layer of *Poria*
472 *cocos* as an effective treatment for chronic renal injury in rats. *J Ethnopharmacol* **2013**, *148*, 403-410.
- 473 24. Zhao, Y. Y.; Feng, Y. L.; Bai, X.; Tan, X. J.; Lin, R. C.; Mei, Q., Ultra performance liquid chromatography-based
474 metabonomic study of therapeutic effect of the surface layer of *Poria cocos* on adenine-induced chronic kidney disease
475 provides new insight into anti-fibrosis mechanism. *PLoS One* **2013**, *8*, e59617.
- 476 25. Chen, D. Q.; Chen, H.; Chen, L.; Tang, D. D.; Miao, H.; Zhao, Y. Y., Metabolomic application in toxicity
477 evaluation and toxicological biomarker identification of natural product. *Chem Biol Interact* **2016**, *252*, 114-130.

- 478 26. Zhao, Y. Y.; Cheng, X. L.; Wei, F.; Bai, X.; Tan, X. J.; Lin, R. C.; Mei, Q., Intrarenal metabolomic investigation of
479 chronic kidney disease and its TGF-beta1 mechanism in induced-adenine rats using UPLC Q-TOF/HSMS/MS(E). *J.*
480 *Proteome Res.* **2013**, *12*, 2692–2703.
- 481 27. Chen, D. Q.; Chen, H.; Chen, L.; Vaziri, N. D.; Wang, M.; Li, X. R.; Zhao, Y. Y., The link between phenotype and
482 fatty acid metabolism in advanced chronic kidney disease. *Nephrology, dialysis, transplantation : official publication of*
483 *the European Dialysis and Transplant Association - European Renal Association* **2017**, *32*, 1154-1166.
- 484 28. Warrington, S. J.; Strutt, H.; Strutt, D., The Frizzled-dependent planar polarity pathway locally promotes
485 E-cadherin turnover via recruitment of RhoGEF2. *Development* **2013**, *140*, 1045-1054.
- 486 29. Andl, T.; Le Bras, G. F.; Richards, N. F.; Allison, G. L.; Loomans, H. A.; Washington, M. K.; Revetta, F.; Lee, R.
487 K.; Taylor, C.; Moses, H. L.; Andl, C. D., Concerted loss of TGFβ-mediated proliferation control and E-cadherin
488 disrupts epithelial homeostasis and causes oral squamous cell carcinoma. *Carcinogenesis* **2014**, *35*, 2602-2610.
- 489 30. Cao, W.; Xu, J.; Zhou, Z. M.; Wang, G. B.; Hou, F. F.; Nie, J., Advanced oxidation protein products activate
490 intrarenal renin-angiotensin system via a CD36-mediated, redox-dependent pathway. *Antioxidants & redox signaling*
491 **2013**, *18*, 19-35.
- 492 31. Breyer, M. D.; Susztak, K., The next generation of therapeutics for chronic kidney disease. *Nature Reviews Drug*
493 *Discovery* **2016**, *15*, 568-588.
- 494 32. He, W.; Tan, R. J.; Li, Y.; Wang, D.; Nie, J.; Hou, F. F.; Liu, Y., Matrix metalloproteinase-7 as a surrogate marker
495 predicts renal Wnt/beta-catenin activity in CKD. *Journal of the American Society of Nephrology : JASN* **2012**, *23*,
496 294-304.
- 497 33. Kong, J.; Du, J.; Wang, Y.; Yang, M.; Gao, J.; Wei, X.; Fang, W.; Zhan, J.; Zhang, H., Focal adhesion molecule
498 Kindlin-1 mediates activation of TGF-beta signaling by interacting with TGF-beta RI, SARA and Smad3 in colorectal
499 cancer cells. *Oncotarget* **2016**, *7*, 76224-76237.

- 500 34. Tsukazaki, T.; Chiang, T. A.; Davison, A. F.; Attisano, L.; Wrana, J. L., SARA, a FYVE domain protein that
501 recruits Smad2 to the TGFbeta receptor. *Cell* **1998**, *95*, 779-91.
- 502 35. Zhang, Z. H.; Vaziri, N. D.; Wei, F.; Cheng, X. L.; Bai, X.; Zhao, Y. Y., An integrated lipidomics and metabolomics
503 reveal nephroprotective effect and biochemical mechanism of Rheum officinale in chronic renal failure. *Sci Rep* **2016**,
504 *6*, 22151.
- 505 36. Zhang, Z. H.; Wei, F.; Vaziri, N. D.; Cheng, X. L.; Bai, X.; Lin, R. C.; Zhao, Y. Y., Metabolomics insights into
506 chronic kidney disease and modulatory effect of rhubarb against tubulointerstitial fibrosis. *Sci Rep* **2015**, *5*, 14472.
- 507 37. Wang, M.; Chen, L.; Liu, D.; Chen, H.; Tang, D. D.; Zhao, Y. Y., Metabolomics highlights pharmacological
508 bioactivity and biochemical mechanism of traditional Chinese medicine. *Chem Biol Interact* **2017**, *273*, 133-141.
- 509 38. Zhao, Y. Y., Metabolomics in chronic kidney disease. *Clin. Chim. Acta* **2013**, *422*, 59-69.
- 510 39. Cybulsky, A. V., Endoplasmic reticulum stress, the unfolded protein response and autophagy in kidney diseases.
511 *Nat Rev Nephrol* **2017**, *advance online publication*.
- 512 40. Sun, Y. B.; Qu, X.; Caruana, G.; Li, J., The origin of renal fibroblasts/myofibroblasts and the signals that trigger
513 fibrosis. *Differentiation; research in biological diversity* **2016**, *92*, 102-107.
- 514 41. Zhang, H.; Han, G. W.; Batyuk, A.; Ishchenko, A.; White, K. L.; Patel, N.; Sadybekov, A.; Zamlenny, B.; Rudd, M.
515 T.; Hollenstein, K.; Tolstikova, A.; White, T. A.; Hunter, M. S.; Weierstall, U.; Liu, W.; Babaoglu, K.; Moore, E. L.;
516 Katz, R. D.; Shipman, J. M.; Garcia-Calvo, M.; Sharma, S.; Sheth, P.; Soisson, S. M.; Stevens, R. C.; Katritch, V.;
517 Cherezov, V., Structural basis for selectivity and diversity in angiotensin II receptors. *Nature* **2017**, *544*, 327-332.
- 518 42. Lichtnekert, J.; Kaverina, N. V.; Eng, D. G.; Gross, K. W.; Kutz, J. N.; Pippin, J. W.; Shankland, S. J.,
519 Renin-Angiotensin-Aldosterone System Inhibition Increases Podocyte Derivation from Cells of Renin Lineage. *Journal*
520 *of the American Society of Nephrology : JASN* **2016**, *27*, 3611-3627.
- 521 43. Ruster, C.; Wolf, G., Renin-angiotensin-aldosterone system and progression of renal disease. *Journal of the*
522 *American Society of Nephrology : JASN* **2006**, *17*, 2985-91.

- 523 44. Nusse, R.; Clevers, H., Wnt/beta-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. *Cell* **2017**,
524 *169*, 985-999.
- 525 45. Surendran, K.; Schiavi, S.; Hruska, K. A., Wnt-dependent beta-catenin signaling is activated after unilateral
526 ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. *Journal*
527 *of the American Society of Nephrology : JASN* **2005**, *16*, 2373-84.
- 528 46. Xiao, L.; Zhou, D.; Tan, R. J.; Fu, H.; Zhou, L.; Hou, F. F.; Liu, Y., Sustained Activation of Wnt/beta-Catenin
529 Signaling Drives AKI to CKD Progression. *J Am Soc Nephrol* **2016**, *27*, 1727-1740.
- 530 47. Lin, X.; Zha, Y.; Zeng, X. Z.; Dong, R.; Wang, Q. H.; Wang, D. T., Role of the Wnt/beta-catenin signaling pathway
531 in inducing apoptosis and renal fibrosis in 5/6-nephrectomized rats. *Molecular medicine reports* **2017**, *15*, 3575-3582.
- 532 48. Meng, X. M.; Tang, P. M.; Li, J.; Lan, H. Y., TGF-beta/Smad signaling in renal fibrosis. *Frontiers in physiology*
533 **2015**, *6*, 82.
- 534 49. Meng, X. M.; Huang, X. R.; Chung, A. C.; Qin, W.; Shao, X.; Igarashi, P.; Ju, W.; Bottinger, E. P.; Lan, H. Y.,
535 Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis. *Journal of the American Society of Nephrology :*
536 *JASN* **2010**, *21*, 1477-87.
- 537 50. Meng, X. M.; Nikolic-Paterson, D. J.; Lan, H. Y., TGF-beta: the master regulator of fibrosis. *Nat Rev Nephrol*
538 **2016**, *12*, 325-338.
- 539 51. Xu, P.; Liu, J.; Derynck, R., Post-translational regulation of TGF- β receptor and Smad signaling. *FEBS Letters*
540 **2012**, *586*, 1871-1884.
- 541 52. Vindevoghel, L.; Lechleider, R. J.; Kon, A.; de Caestecker, M. P.; Uitto, J.; Roberts, A. B.; Mauviel, A.,
542 SMAD3/4-dependent transcriptional activation of the human type VII collagen gene (COL7A1) promoter by
543 transforming growth factor beta. *Proceedings of the National Academy of Sciences of the United States of America*
544 **1998**, *95*, 14769-74.

545 53. Liu, F. Y.; Li, X. Z.; Peng, Y. M.; Liu, H.; Liu, Y. H., Arkadia regulates TGF-beta signaling during renal tubular
546 epithelial to mesenchymal cell transition. *Kidney international* **2008**, 73, 588-594.

547 54. Xie, F.; Zhang, Z.; van Dam, H.; Zhang, L.; Zhou, F., Regulation of TGF-beta Superfamily Signaling by SMAD
548 Mono-Ubiquitination. *Cells* **2014**, 3, 981-93.

549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567

Figure legends

Figure 1. Novel triterpenoids from SLPC. (A) Chemical structures of compounds PZF-PZH. (B) Key HMBC correlations for compounds PZF-PZH. (C) Key NOESY correlations for compounds PZF-PZH.

Figure 2. PZF, PZG and PZH attenuated TIF and podocyte injury induced by Ang II and TGF- β 1. (A) Representative Western blot analyses revealed that the 10 μ M of PZF, PZG and PZH exhibited stronger suppression of TGF- β 1-induced high expression of collagen I. (B) Representative Western blot analyses revealed that triterpene PZG and PZH exhibited stronger suppression of TGF- β 1-induced TIF in HK-2 cells, and diterpene PZF hardly reversed the abnormality. (C) Graphic presentation of collagen I, fibronectin, α -SMA and E-cadherin expression in different groups as indicated. (D) Representative Western blot analyses revealed that PZG and PZH performed better inhibitory effect on Ang II-induced TIF in HK-2 cells, and diterpene PZF was weaker. (E) Graphic presentation of collagen I, fibronectin, α -SMA and E-cadherin expression in different groups as indicated. (F) The abnormal mRNA expression of collagen I, fibronectin, α -SMA and vimentin were decreased by PZG and PZH, while down-regulated E-cadherin was increased after PZG and PZH stimulation. (G) Representative Western blot analyses revealed that PZG and PZH exhibited powerful inhibitory effect of TGF- β 1-induced podocyte injury, and PZF showed no inhibitory effect in MPC5. (H) Graphic presentation of podocin, nephrin, podocalyxin and synaptopodin expression in different groups as indicated. (I) Representative Western blot analyses revealed that PZG and PZH exhibited stronger suppression of podocyte injury caused by Ang II, and PZF hardly reverse the injury in MPC5. (J) Graphic presentation of podocin, nephrin, podocalyxin and synaptopodin expression in different groups as indicated. (K) Representative micrographs showed vimentin expression in different groups in HK-2 cells. Each data represents the mean $\pm$ SD for groups of different group. #P<0.05; ##P<0.01 versus CTL. *P<0.05; **P<0.01 versus TGF- β 1 or Ang II stimulation.

Figure 3. PZF, PZG and PZH inhibited the activation of RAS. (A) Representative Western blot analyses revealed that triterpene PZG and PZH down-regulated the activation of RAS in HK-2 cells after TGF- β 1 stimulation, but diterpene PZF showed no effect. (B) Graphic presentation of AGT, renin, ACE and AT1 expression in different groups

as indicated. (C) Representative Western blot analyses revealed that Ang II up-regulated the protein expression of RAS components, and PZG and PZH reversed the abnormal expression of AGT, renin, ACE and AT1 protein, but PZF performed no effect in HK-2 cells. (D) Graphic presentation of AGT, renin, ACE and AT1 expression in different groups as indicated. Each data represents the mean $\pm$ SD for groups of different group. #P<0.05; ##P<0.01 versus CTL. *P<0.05; **P<0.01 versus TGF- β 1 or Ang II stimulation.

Figure 4. PZF, PZG and PZH suppressed activated Wnt/ β -catenin and its downstream target genes expression.

(A) Representative Western blot analyses demonstrated that triterpene PZG and PZH decreased activated Wnt/ β -catenin and its downstream targets after TGF- β 1 stimulation in HK-2 cells, but diterpene PZF showed no effect. (B) Graphic presentation of Wnt1, β -catenin, active β -catenin, snail, twist, MMP-7, PAI-1 and Fsp-1 expression in different groups as indicated. (C) Representative Western blot analyses showed that Ang II stimulated the accumulation of β -catenin and active β -catenin, and PZG and PZH decreased the abnormal expression of Wnt/ β -catenin and its downstream targets, but PZF performed no effect in HK-2 cells. (D) Graphic presentation of Wnt1, β -catenin, active β -catenin, snail, twist, MMP-7, PAI-1 and Fsp-1 expression in different groups as indicated. (E) TGF- β 1 up-regulated Wnt1, Wnt2, Wnt3, Wnt3a, Wnt7a and Wnt8a expression, and their abnormality were reversed after given PZG and PZH. (F) Representative micrographs showed β -catenin expression in different groups in HK-2 cells. (G) Representative Western blot analyses revealed that the inhibitory effect of PZG and PZH were obvious in TGF- β 1-induced the activation of Wnt/ β -catenin, but PZF showed no effect in MPC5. (H) Graphic presentation of Wnt1, β -catenin, active β -catenin, snail, twist, MMP-7, PAI-1 and Fsp-1 expression in different groups as indicated. (I) Representative Western blot analyses indicated that PZG and PZH reversed the abnormal expression of Wnt1, β -catenin, active β -catenin, snail, twist, MMP-7, PAI-1 and Fsp-1 protein caused by Ang II in MPC5, but PZF performed no effect in HK-2 cells. (J) Graphic presentation of Wnt1, β -catenin, active β -catenin, snail, twist, MMP-7, PAI-1 and Fsp-1 expression in different groups as indicated. Each data represents the mean $\pm$ SD for groups of different group. #P<0.05; ##P<0.01 versus CTL. *P<0.05; **P<0.01 versus TGF- β 1 or Ang II stimulation.

Figure 5. PZF, PZG and PZH selectively inhibits TGF- β 1/Smad3 pathway. (A) Representative Western blot analyses showed that triterpene PZG and PZH exhibited stronger suppression of TGF- β 1-induced up-regulation of TGF β RI and p-Smad3 in HK-2 cells, and diterpene PZF hardly reversed the abnormality. (B) Graphic presentation of TGF β RI, TGF β RII, p-Smad2, Smad2, p-Smad3, Smad3, Smad4 and Smad7 expression in different groups as indicated. (C) Representative Western blot analyses revealed that PZG and PZH performed better inhibitory effect on Ang II-induced high expression of TGF β RI and p-Smad3 in HK-2 cells, and diterpene PZF was weaker. (D) Graphic presentation of TGF β RI, TGF β RII, p-Smad2, Smad2, p-Smad3, Smad3, Smad4 and Smad7 in different groups as indicated. (E) Representative micrographs show p-Smad3 expression in different groups in HK-2 cells. (F) Representative Western blot analyses indicated that PZG and PZH exhibited powerful inhibitory effect of TGF- β 1-induced activated TGF- β 1/Smad3 pathway, and PZF showed no inhibitory effect in MPC5. (G) Graphic presentation of TGF β RI, TGF β RII, p-Smad2, Smad2, p-Smad3, Smad3, Smad4 and Smad7 expression in different groups as indicated. (H) Representative Western blot analyses demonstrated that PZG and PZH exhibited stronger suppression of activated TGF- β 1/Smad3 caused by Ang II, and PZF hardly reverse the injury in MPC5. (I) Graphic presentation of TGF β RI, TGF β RII, p-Smad2, Smad2, p-Smad3, Smad3, Smad4 and Smad7 expression in different groups as indicated. Each data represents the mean $\pm$ SD for groups of different group. #P<0.05; ##P<0.01 versus CTL. *P<0.05; **P<0.01 versus TGF- β 1 or Ang II stimulation.

Figure 6. PZF, PZG and PZH selectively interrupt the interactions of Smad3 with TGF β RI and SARA in HK-2 cells. (A) Representative Western blot analyses revealed that TGF- β 1 enhanced the interactions of TGF β RI and TGF β RII with Smad2 and Smad3, while PZF, PZG specifically broke the interaction between TGF β RI and Smad3, and PZF showed no effect. (B) Graphic presentation of representative Western blot in different groups as indicated. (C) Representative Western blot analyses demonstrated that PZF, PZG and PZH performed no effect on the connection of Smad2 with TGF β RI and TGF β RII. (D) Graphic presentation of representative Western blot in different groups as indicated. (E) Representative Western blot analyses revealed that apart from PZF, PZG and PZH owned powerful

inhibitory effect on the interactions of Smad3 with TGF β RI and TGF β RII. (F) Graphic presentation of representative Western blot in different groups as indicated. (G) Representative Western blot analyses indicated that PZF, PZG and PZH affected the interactions of SARA with TGF β RI and Smad3, but hardly changed the interaction of SARA with Smad2. (H) Graphic presentation of representative Western blot in different groups as indicated. (I) CO-IP demonstrated that PZG and PZH only influenced the interaction between SARA and Smad3. (J) Graphic presentation of representative Western blot in different groups as indicated. (K) PZG and PZH broke the interactions of SARA with TGF β RI and Smad3. Each data represents the mean $\pm$ SD for groups of different group. #P<0.05; ##P<0.01 versus CTL. *P<0.05; **P<0.01 versus TGF- β 1 or Ang II stimulation.

Figure 7. PZF, PZG and PZH performed no anti-fibrotic effect after knockdown of Smad3. (A) Specific Smad3 siRNA evidently down-regulated protein expression of Smad3 in HK-2. Graphic presentation of β -catenin protein expression in different groups as indicated. (B) PZF, PZG and PZH had no effect on the RNAi of Smad3. Graphic presentation of β -catenin protein expression in different groups as indicated. (C) After knockdown Smad3, PZF, PZG and PZH performed no effect on renal fibrosis. (D) Graphic presentation of collagen I, fibronectin, α -SMA and E-cadherin expression in different groups as indicated. Each data represents the mean $\pm$ SD for groups of different group. #P<0.05; ##P<0.01 versus CTL. *P<0.05; **P<0.01 versus TGF- β 1 or Ang II stimulation.

Figure 8. PZG and PZH inhibited EMT by suppressing the activation of RAS, Wnt/ β -catenin and TGF- β 1/Smad pathways. PZG and PZH selectively inhibited the phosphorylation of Smad3 to attenuate renal fibrosis. PZG and PZH suppressed the activation of RAS and performed like the combination of ACEI and ARB. PZG and PZH decreased Wnt1 and β -catenin protein expression.

660 **Table 1 Primers of Homo sapiens for qRT-PCR (5'→3') of EMT and Wnts genes**

Gene	Forward	Reverse	Product Size (bp)
Collagen I	TGTGCCACTCTGACTGGAAG	CGCCATACTCGAACTGGAATC	228
Fibronectin	CCACAGTGGAGTATGTGGTTAG	CAGTCCTTTAGGGCGATCAAT	104
α -SMA	GATGGTGGGAATGGGACAAA	GCCATGTTCTATCGGGTACTTC	94
Vimentin	GATTCACTCCCTCTGGTTGATAC	GTCATCGTGATGCTGAGAAGT	108
E-cadherin	CTTCTGCTGATCCTGTCTGATG	TGCTGTGAAGGGAGATGTATTG	144
Wnt1	CGGCGTTATCTTCGCTATCA	GTAGTCACACGTGCAGGATT	95
Wnt2	CGGGAATCTGCCTTTGTTTATG	TTGGATCACAGGAACAGGATTT	103
Wnt3	CTGACTTCGGCGTGTTAGT	CCTCGTTGTGTGCTTGTC	93
Wnt3a	CAAGATTGGCATCCAGGAGT	ATGAGCGTGTCAGTCAAAG	173
Wnt7a	CGTGCTCAAGGACAAGTACA	GTACGACAGTGGCTTCTTGAT	103
Wnt8a	CAGTGAGAGCCACCATGAAA	CCTGGTCATACTTGGCCTTTAG	132
β -actin	ACAAGCCACAAGATTACAAG	ATCAGCAG TCTCATTCCAA	92

661

662

663

664

665

666

667

668 **Table 2 NMR data for PZF (500 MHz for ¹H and 125 MHz for ¹³C, in pyridine)**

Position	C	H	HMBC (H to C)
1	39.0 (t)	1.51, 2.30 (m)	3, 4, 5, 10, 20
2	30.4 (d)	1.41 (m)	4, 10
3	35.3 (t)	2.54 (m)	4, 18, 19
4	48.0 (s)		
5	45.8 (d)	2.55 (m)	4, 7, 10, 18, 19, 21
6	19.4 (t)	1.63, 1.77 (m)	8, 18
7	30.8 (t)	2.88, 2.95 (m)	5, 8, 9, 14
8	135.5 (s)		
9	148.1 (s)		
10	37.6 (s)		
11	125.1 (d)	7.29 (d, <i>J</i> = 8.2 Hz)	3, 8, 10
12	124.7 (d)	7.12 (dd, <i>J</i> = 8.1, 1.8 Hz)	11, 13, 15
13	146.3 (s)		
14	127.7 (d)	6.95 (d, <i>J</i> = 1.3 Hz)	7, 9, 12, 15
15	34.3 (d)	2.81 (m)	12, 14
16	24.6 (q)	1.23 (s)	13, 15, 17
17	24.6 (q)	1.23 (s)	13, 15, 16
18	176.4 (s)		
19	17.5 (q)	1.49 (s)	3, 5, 1'
20	181.4 (s)		
21	25.7 (q)	1.21 (s)	1, 5, 10

1'	37.8 (t)	1.84, 2.08 (m)	19, 2'-6'
2'-6'	30.0 - 30.4 (t)	1.26 – 1.30	7'
7'	32.5 (t)	1.25	9'
8'	23.4 (t)	1.27	
9'	14.7 (q)	0.87 (m)	7', 8'

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687 **Table 3 NMR data for PZG and PZH (500 MHz for ¹H and 125 MHz for ¹³C, in pyridine)**

Position	PZG		PZH	
	¹³ C	¹ H	¹³ C	¹ H
1	36.8 (t)	2.15, 1.93 (m)	33.1 (s)	1.73, 1.23 (m)
2	30.7 (t)	2.52 (dd, 10.7, 5.0)	23.8 (t)	2..30 (m)
3	177.0 (s)		77.4 (s)	4.60 (s)
4	149.7 (s)		42.8 (s)	
5	51.2 (d)	2.35 (s)	186.6 (s)	
6	28.9 (t)	2.56, 2.07 (m)	126.7 (d)	6.56 (s)
7	118.4 (d)	5.30 (t)	199.1 (s)	
8	142.3 (s)		140.1 (s)	
9	138.0 (s)		162.9 (s)	
10	39.3 (s)		43.6 (s)	
11	120.8 (d)	5.36 (br s)	30.3 (t)	1.27 (m)
12	37.5 (t)	2.71 (d, 17.9), 2.49 (m)	29.4 (t)	2.28, 2.13
13	46.0 (s)		46.9 (s)	
14	49.0 (s)		47.3 (s)	
15	44.1 (t)	2.43 (d, 8.7), 1.82 (m)	46.3 (t)	3.03, 2.96
16	76.8 (d)	4.53 (m)	76.1 (d)	4.48 (m)
17	58.0 (d)	2.87 (dd, 11.2, 6.0)	56.2 (d)	2.84 (m)
18	18.7 (q)	1.11 (s)	18.4 (q)	1.17 (s)
19	22.6 (q)	1.05 (s)	23.4 (q)	1.38 (s)
20	49.6 (d)	2.98 (dt, 11.2, 3.4)	49.0 (d)	2.96 (m)

21	179.2 (s)		179.5 (s)	
22	33.9 (t)	2.45 (m), 2.36 (s)	33.5 (t)	2.40, 2.54 (m)
23	23.8 (t)	2.10 (m), 1.89 (m)	23.8 (t)	2.30 (m)
24	45.3 (t)	1.85 (m), 1.72 (s)	156.4 (s)	
25	70.0 (s)		34.5 (d)	2.28 (m)
26	30.5 (q)	1.36 (s)	22.3 (q)	1.00 (s)
27	30.3 (q)	1.36 (s)	22.1 (q)	1.01 (s)
28	112.6 (t)	4.85, 4.78 (br s)	27.9 (q)	1.41 (s)
29	22.6 (q)	1.75 (s)	27.6 (q)	1.34 (s)
30	25.3 (q)	1.51 (s)	25.5 (q)	1.64 (s)
31			107.1 (t)	5.02, 4.87 (m)

688

689

690

691

692

693

694

695

696

697

698

699

Figure 1

712 **Figure 2**

713

714

715

716

717 **Figure 3**

735 **Figure 4**

736

737

738

739 Figure 5

Figure 6

Figure 7

781 Figure 8

792 TOC graphic

793

1021x693mm (96 x 96 DPI)